Atriance launched for lymph cancer

GSK has launched Atriance (nelarabine) for the treatment of patients with T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded, or has relapsed, following treatment with at least two chemotherapy regimens.

Further information: GSK 0800 221441

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Free coronavirus news and resources on MIMS, MIMS Learning and GPonline

Free coronavirus news and resources on MIMS, MIMS Learning and GPonline

As the coronavirus crisis continues, we at Haymarket...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Transdermal estradiol spray offers new treatment option for HRT

Transdermal estradiol spray offers new treatment option for HRT

Lenzetto (estradiol) is the first transdermal spray...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Flutiform K-haler.
Use our constantly updated...